Altimmune Inc
Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart
Altimmune on Wednesday said its experimental drug helped patients shed weight but also minimized the loss of muscle mass in a midstage trial, a finding that could set it apart in a potentially crowded market. Altimmune is one of several smaller biotech companies that are pushing to compete directly with Novo Nordisk and Eli Lilly […]
Read MoreViking stock doubled Tuesday. In this article's the place the following moves in the weight problems room could arrive from
Anti-weight problems drugmakers Novo Nordisk and Eli Lilly have a big lead on their competitiveness, but supplied the large and beneficial marketplace, rivals are nevertheless keen to sign up for the race. Bank of America analyst Geoff Meacham has been quite bullish about the option, which he phone calls “unparalleled” offered the prevalence of obesity […]
Read MoreThe weight loss drug boom isn't over yet — here's what to expect in the year ahead
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. […]
Read MoreIf you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies — […]
Read MoreHere are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don’t expect this duopoly to end soon, analysts say. But other companies — both big and small — are hoping to grab a piece of this lucrative market. In a research note, Piper Sandler analyst Yasmeen Rahimi said the firm is tracking more […]
Read MoreGoldman Sachs suggests this minimal-recognized biotech inventory can double on potentially ‘blockbuster’ earnings
Investors should really invest in biopharma stock Altimmune as it can double from below relying on the achievement of a new weight problems drug, in accordance to Goldman Sachs. Analyst Corinne Jenkins initiated protection of Altimmune with a invest in score, indicating she strongly expects a analyze on pemvidutide as a treatment for obesity will […]
Read More